Thermo Fisher stock holds on steady earnings base
Published on 07/27/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Thermo Fisher Scientific Inc. (ISIN US8835561023) is supported by a 2025 scale profile that still stands out in life sciences tools: revenue reached $43.6 billion, adjusted EPS was $21.75, and free cash flow came in at $5.7 billion. Those figures come from the company’s 2025 reporting, while the latest market context points to a market capitalization of about $215 billion.
Revenue above $43 billion
Thermo Fisher reported 2025 revenue of $43.6 billion, which gives the group a large base across diagnostics, analytical instruments, specialty diagnostics, and lab products. In the same reporting period, adjusted EPS was $21.75, a concrete reminder that earnings power still matters more than any single quarter’s noise.
The comparison that matters is scale versus cash generation: $43.6 billion of revenue sat alongside $5.7 billion of free cash flow in 2025. That combination is important because it shows how the business converts a broad installed base into cash, not just sales.
Cash flow at $5.7 billion
Free cash flow of $5.7 billion in 2025 gives Thermo Fisher room to fund operations, capital spending, and capital returns from internal generation. Adjusted EPS of $21.75 in the same year also shows that profitability remained substantial even after a post-pandemic normalization in life sciences demand.
For investors, the main takeaway is that Thermo Fisher stock is anchored by recurring demand from laboratories, hospitals, and pharma customers, rather than a single product cycle. The latest market value of about $215 billion suggests the market still assigns a premium to that mix of scale and resilience.
What the business sells
Thermo Fisher’s product set spans instruments, reagents, consumables, and services used in research and clinical workflows. That mix matters because consumables and services typically smooth the cycle better than pure hardware exposure, and the 2025 figures above show the scale of that model.
The company’s 2025 revenue of $43.6 billion and free cash flow of $5.7 billion remain the most useful recent anchors for Thermo Fisher stock. They frame the current valuation discussion better than any slogan about the business itself.
Market value near $215 billion
Thermo Fisher Scientific Inc. carried a market capitalization of about $215 billion in the latest market context used here. That is large enough to keep the name in the global large-cap health care and tools conversation, even when short-term trading is driven by sector rotation rather than a single headline.
The stock closing level is omitted because no dated live quote was available in the available search results, but the valuation anchor remains the $215 billion market capitalization. For context, that market value sits beside 2025 revenue of $43.6 billion, adjusted EPS of $21.75, and free cash flow of $5.7 billion.
Thermo Fisher Scientific Inc. fact box
- Company: Thermo Fisher Scientific Inc.
- ISIN: US8835561023
- Ticker: NYSE: TMO
- Trading venue: NYSE
- Market capitalization: about $215 billion
- Sector / Industry: Health Care / Life Sciences Tools and Services
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
